Medicare Unlikely To Embrace Cost Effectiveness In Early Price Negotiations – ICER’s Pearson

 
• By Cathy Kelly
  
CMS' Approach To Valuing Drugs Remains To Be Seen • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Market Access

More from Pink Sheet